Synapse - Maria Palomba

Results (448)

Successful incorporation of electronic patient-reported outcomes using PROMIS-29 into standard of care for lymphoma patients receiving CD19-directed chimeric antigen receptor T (CAR T) cell therapy

Meeting Abstract

Shah, G. L.; Scordo, M.; Sauter, C.; Batlevi, C.; Dahi, P. B.; Lin, R.; Palomba, M. L.; Perales, M. A.; Giralt, S. A.
Quality of Life Research (2021)

Fulltext@MSK | Save

Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial

Meeting Abstract

Ghosh, N.; Salles, G. A.; Lossos, I. S.; Palomba, M. L.; Mehta, A.; Casasnovas, O.; Stevens, D. A.; Katakam, S.; Knapp, A.; Nielsen, T.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

A proof-of-principle study of split-course bridging radiotherapy prior to commercial CD19 CAR T-cell therapies for patients with relapsed or refractory B-cell lymphomas

Meeting Abstract

Imber, B. S.; Palomba, M. L.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial

Journal Article

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: Is 4 Gy suitable for curable patients?

Journal Article

Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Casey, D. L.; Yang, J. C.; Wijentunga, N. A.; Shepherd, A.; Hajj, C.; Qi, S.; more...
Blood Advances (2021)

Fulltext@MSK | Save

Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials

Journal Article

Palomba, M. L.; Jun, M. P.; Lymp, J.; Nguyen, A.; McGarvey, N.; Gitlin, M.; Pelletier, C.; Keating, S. J.; Godwin, J.
Leukemia and Lymphoma (2021)

Fulltext@MSK | Save

Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Phase 1/2 BRUIN study results

Meeting Abstract

Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fahkri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T. S.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts